Treatment of movement disorders in autism spectrum disorders

Autism Spectrum Disorders

Volumn , Issue , 2003, Pages 273-346

  Brǎsi Ć, James Robert ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BELLEVUE HOSPITAL CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 14644423403     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (313)

1. Dobbinson S, Perkins MR, Boucher J. Structural patterns in conversations with a woman who has autism. J Commun Disord 1998; 31:113-134.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text revision. Washington, DC: American Psychiatric Publishing, 2000.
3. Teitelbaum P, Teitelbaum O, Nye J, Fryman J, Maurer RG. Movement analysis in infancy may be useful for early diagnosis of autism. Proc Natl Acad Sci USA 1998; 95:13982-13987.
4. Brašić JR. Movements in autistic disorder. Med Hypotheses 1999; 53(1):48-49.
5. Brašić JR. Pervasive developmental disorder: Asperger syndrome. eMedicine Journal Jan 7, 2002; 3(1).
6. Brašić JR: Pervasive developmental disorder: autism. eMedicine Journal Feb 19, 2002; 3(2).
7. Brašić JR, Gianutsos JG. Neuromotor assessment and autistic disorder. Autism Int J Res Pract 2000; 4(3):287-298.
8. Gillberg C, Coleman M. The Biology of the Autistic Syndromes. 3rd ed. London: MacKeith Press, 2000.
9. Brašić JR, Barnett JY. Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid. Psychol Rep 1997; 80:163-170.
10. National Institute of Mental Health (NIMH), Alcohol, Drug Abuse, and Mental Health Administration, Public Health Service, Department of Health, Education, and Welfare. Abnormal Involuntary Movement Scale (AIMS). Psychopharmacol Bull 1988; 24(4):781-783.
11. Brašić JR, Bronson B: Tardive dyskinesia. eMedicine Journal May 20, 2002; 3(5).
12. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S. A Children’s Global Assessment Scale (CGAS) (for children 4 to 16 years of age). Psychopharmacol Bull 1985; 21(4):747-748.
13. Brašić JR, Will MV, Ahn SC, Nadrich RH, McNally G. A review of the literature and a preliminary study of family compliance in a developmental disabilities clinic. Psychol Rep 1998; 82:275-286.
14. Brašić JR, Nadrich RH, Kleinrock S, Brathwaite C. Do families comply with child and adolescent psychopharmacology? Child Adolesc Psychopharmacol News 2001; 6(2):6, 7, 10.
15. Fleischhacker WW, Bergmann KJ, Perovich R, Pestreich LK, Borenstein M, Lieberman J, Kane J. The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol Bull 1989; 25:222-226.
16. Medical Editors’ Trial Amnesty (META). J Neurol 1998; 245:563-564.
17. Brašić JR. Differentiating myoclonus from tics. Psychol Rep 2000; 86:155-156.
18. Brašić JR, Young JG, Furman J, Conte RM, Baisley WE, Jaslow RI. Psychoactive Medication Quality Assurance Rating Survey (PQRS). J Dev Phys Disabil 1997; 9:311-336.
19. Brašić JR, Furman J, Conte RM, Baisley WE, Nadrich RH, Kaplan D, Ahmad R, Rodriguez M, Mendonça MF, Will MV. Quality assurance of treatments for Tourette syndrome and other tic disorders [abstr]. 3rd International Scientific Symposium on Tourette Syndrome, New York, June 4-6, 1999, p 20.
20. Brašić JR, Furman J, Conte RM, Baisley WE, Jaslow RI. Psychoactive Medication Quality Assurance Rating Survey (PQRS) screening criteria. J Dev Phys Disabil. In press.
21. Brašić JR, Furman J, Conte RM, Baisley WE, Jaslow RI. Improving the quality of the utilization of psychoactive medication. J Dev Phys Disabil. In press.
22. International Classification of Diseases. Ninth Revision, Clinical Modification, Fifth Edition. Salt Lake City: Medicode Publications, 1997.
23. Physicians’ Desk Reference. 56th ed. Montvale, NJ: Medical Economics, 2002. www.PDR.net.
24. Brasic JR, Barnett JY, Ahn SC, Nadrich RH, Will MV, Clair A. Clinical assessment of self-injurious behavior. Psychol Rep 1997; 80:155-160.
25. Campbell M. Timed Stereotypies Rating Scale. Psychopharmacol Bull 1985; 21(3):1082.
26. Steffenburg S, Gillberg C, Steffenburg U. Psychiatric disorders in children and adolescents with mental retardation and active epilepsy. Arch Neurol 1996; 53: 904-912.
27. Brašić JR, Zagzag D, Kowalik S, Prichep L, John ER, Liang HG, Kutchko B, Cancro R, Sheitman BB, Buchsbaum M, Brathwaite C. Progressive catatonia. Psychol Rep 1999; 84:239-246.
28. Brašić JR, Zagzag D, Kowalik S, Prichep L, John ER, Barnett JY, Bronson B, Nadrich RH, Cancro R, Buchsbaum M, Brathwaite C. Clinical manifestations of progressive catatonia. Ger J Psychiatry 2000; 3:13-24.
29. Brašić JR. Catatonia. eMedicine Journal Sept 27, 2002; 3(9).
30. Brašić JR, Barnett JY, Kowalik S, Prichep L, John ER, Nadrich RH, Will MV, Bronson B, Ahmad R, Kurz L, Brathwaite C, Cancro R. Catatonia in pervasive developmental disorders [abstr]. Mov Disord 2001; 16(suppl 1):S46-S47.
31. Brašić JR, Zagzag D, Kowalik S, Prichep L, John ER, Buchsbaum M, Barnett JY, Nadrich RH, Kaplan D, Ahmad R, Mendonça MF, Rodriguez M, Bronson B, Cancro R, Kurz L, Brathwaite C. Chronic motor tics are a manifestation of progressive catatonia [abstr]. 3rd International Scientific Symposium on Tourette Syndrome, New York, June 4-6, 1999, p 21.
32. Brašić JR. Conversion disorder in childhood. Ger J Psychiatry 2002; 5(2):54-61.
33. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676.
34. Brašić JR, Barnett JY. Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid. Psychol Rep 1997; 80:163-170.
35. Brašić JR, Barnett JY, Aisemberg P, Ahn SC, Nadrich RH, Kaplan D, Ahmad R, Mendonça MF. Dyskinesias subside off all medication in a boy with autistic disorder and severe mental retardation. Psychol Rep 1997; 81:755-767.
36. Fleischhacker WW, Bergmann KJ, Perovich R, Pestreich LK, Borenstein M, Lieberman J, Kane J. The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol Bull 1989; 25:222-226.
37. Brašić JR, Barnett JY, Sheitman BB, Lafargue RT, Ahn SC. Clinical assessment of adventitious movements. Psychol Rep 1998; 83:739-750.
38. Brašić JR. Should people with nocturnal leg cramps drink tonic water and bitter lemon? Psychol Rep 1999; 84:355-367.
39. Brašić JR. Quinine-induced thrombocytopenia in a 64-year-old man who consumed tonic water to relieve nocturnal leg cramps [letter]. Mayo Clinic Proc 2001; 76:863-864.
40. Jankovic J. Stereotypies. In: Marsden CD, Fahn S, eds. Movement Disorders 3. Oxford, England: Butterworth-Heinemann, 1994:503-517.
41. Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord 2000; 30:237-243.
42. Brašić JR. Clinical assessment of tics. Psychol Rep 2001; 89:48-50.
43. Blakeslee S. Movement may offer early clue to autism. New York Times, Jan 26, 1999, p F3.
44. Goffman E. Stigma: Notes on the Management of Spoiled Identity. Englewood Cliffs, NJ: Prentice-Hall, 1963.
45. Brašić JR. Autistic disorder and intentional aggression. Phillips J, interviewer. New York: WPIX news, Dec 19 and 20, 1994.
46. Nicolson R, Awad G, Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998; 37:372-376.
47. McDougle CJ, Scahill L, McCracken JT, Aman MG, Tierney E, Arnold LE, Freeman BJ, Martin A, McGough JJ, Cronin P, Posey DJ, Riddle MA, Ritz L, Swiezy NB, Vitiello B, Volkmar FR, Votolato NA, Walson P. Research Units on Pediatric Psychopharmacology (RUPP) autism network: background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin North Am 2000; 9: 201-224.
48. Williams H, Clarke R, Bouras N, Martin J, Holt G. Use of the atypical antipsychotics olanzapine and risperidone in adults with intellectual disability. J Intellect Disabil Res 2000; 44:164-169.
49. Haut F, Clos S. Acute akathisia and sodium valproate. Int J Psychiatry Clin Pract 2001; 5:219-222.
50. Brašić JR, Furman JW, Conte RM, Baisley WE. Continuous quality improvement in child and adolescent psychopharmacology. Child Adolesc Psychopharmacol News 1999; 4(3):9-10.
51. Brašić JR, Furman J, Conte RM, Baisley WE, Jaslow RI. Assuring the quality of the utilization of psychoactive medication by people with mental retardation and developmental disabilities by assessing dosages. Ger J Psychiatry 2000; 3(3): 7-12. www.gjpsy.uni-goettingen.de/gjp-article-brasic2.pdf.
52. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997; 36:835-843.
53. Locascio JJ, Malone RP, Small AM, Kafantaris V, Ernst M, Lynch NS, Overall JE, Campbell M. Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacol Bull 1991; 27(2):119-126.
54. Armenteros JL, Adams PB, Campbell M, Eisenberg ZW. Haloperidol-related dyskinesias and prenatal and perinatal complications in autistic-children. Psychopharmacol Bull 1995; 31:363-369.
55. Advokat CD, Mayville EA, Matson JL. Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Res Dev Disabil 2000; 21:75-84.
56. Simonic I, Gericke GS, Lippert M, Schoeman JF. Additional clinical and cytogenetic findings associated with Rett syndrome. Am J Med Genet 1997; 74:331-337.
57. Berger-Sweeney J, Hohmann CF. Behavioral consequences of abnormal cortical development: insights into developmental disabilities. Behav Brain Res 1997; 86: 121-142.
58. Hohmann CF, Berger-Sweeney J. Cholinergic regulation of cortical development and plasticity: new twists to an old story. Perspect Dev Neurobiol 1998; 5:401-425.
59. Wan M, Zhao K, Lee SSJ, Francke U. MECP2 truncating mutations cause histone H4 hyperacetylation in Rett syndrome. Hum Molec Genet 2001; 10:1085-1092.
60. Lee SSJ, Wan M, Francke U. Spectrum of MECP2 mutations in Rett syndrome. Brain Dev 2001; 23(suppl 1):S138-S143.
61. Francke U. Understanding Rett Syndrome: where are we? [abstr]. 3rd Annual Rett Syndrome Symposium, Baltimore, June 17-19, 2002. Cincinnati: Rett Syndrome Research Foundation (RSRF), 2002:1.
62. Bailey MES, Mash V, Hever AM, Boxer M, Ørstavik KH, Reilly S, Kerr AM, Cass H, Charman T. A detailed genotype-phenotype correlation study in Rett syndrome [abstr]. 3rd Annual Rett Syndrome Symposium, Baltimore, June 17-19, 2002. Cincinnati: Rett Syndrome Research Foundation (RSRF), 2002:35.
63. Vaudry D, Stork PJS, Lazarovici P, Eiden LE. Signaling pathways for PC12 cell differentiation: making the right connections. Science 2002; 296:1648-1649. www.sciencemag.org.
64. Stearns NA, Floerke-Nashner L, Berger-Sweeney J. Behavioral characterization of a mouse model of Rett syndrome [abstr]. 3rd Annual Rett Syndrome Symposium, Baltimore, June 17-19, 2002. Cincinnati: Rett Syndrome Research Foundation (RSRF), 2002:33.
65. Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice [letter]. Nat Genet 2001; 27:327-331.
66. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett syndrome: MeCP2 levels display tissue-and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet 2002; 11:115-124.
67. Akbarian S, Chen RZ, Gribnau J, Rasmussen TP, Fong H-F, Jaenisch R, Jones EG. Expression pattern of the Rett syndrome gene MeCP2 in primate prefrontal cortex. Neurobiol Dis 2001; 8:784-791.
68. Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome [letter]. Nat Genet 2001; 27:322-327.
69. Christodoulou J, Grimm A, Maher T, Bennetts B. RettBASE—the IRSA MECP2 variation database: a new mutation database offering enhanced capabilities [abstr]. 3rd Annual Rett Syndrome Symposium, Baltimore, June 17-19, 2002. Cincinnati: Rett Syndrome Research Foundation (RSRF), 2002:38-39.
70. Kriaucionis S, Coenraads M, Hendrich B. The MeCP2 Mutation Database: http://homepages.ed.ac.uk/skirmis[abstr]. 3rd Annual Rett Syndrome Symposium, Baltimore, June 17-19, 2002. Cincinnati: Rett Syndrome Research Foundation (RSRF), 2002:40.
71. Leonard H, Colvin L, Fyfe S, Christodoulou J, Raffaele L, Leonard S, Schiavello T, Ellaway C, Davis M, De Kierk N. Now that the gene has been found: describing the phenotype in Rett syndrome using a national database [abstr]. 3rd Annual Rett Syndrome Symposium, Baltimore, June 17-19, 2002. Cincinnati: Rett Syndrome Research Foundation (RSRF), 2002:41-42.
72. Blue ME, Naidu S, Johnston MV. Development of amino acid receptors in frontal cortex from girls with Rett sydrome. Ann Neurol 1999; 45:541-545.
73. Wenk GL, Hauss-Wegrzyniak B. Altered cholinergic function in the basal forebrain of girls with Rett syndrome. Neuropediatrics 1999; 30:125-129.
74. Horska A, Naidu S, Herskovits EH, Wang PY, Kaufmann WE, Barker PB. Quantitative 1H MR spectroscopic imaging in early Rett syndrome. Neurology 2000; 54: 715-722.
75. Narbona J. Rett syndrome as a hodogenetic neural disorder. Revista de Neurologia 1999; 28:97-101.
76. Burroni L, Aucone AM, Volterrani D, Hayek Y, Bertelli P, Vella A, Zappella M, Vattimo A. Brain perfusion abnormalities in Rett syndrome: a qualitative and quantitative SPET study with 99Tcm-ECD. Nucl Med Commun 1997; 18:527-534.
77. Blue ME, Naidu S, Johnston MV. Altered development of glutamate and GABA receptors in the basal ganglia of girls with Rett syndrome. Exp Neurol 1999; 156: 345-352.
78. Chiron C, Bulteau C, Loc’h C, Raynaud C, Garreau B, Syrota A, Mazière B. Dopaminergic D2 receptor SPECT imaging in Rett syndrome: increase of specific binding in striatum. J Nucl Med 1993; 34:1717-1721.
79. Stoessl AJ, Dobko T, Morrison KS, Oakes T, Ho HH, Snow BJ, Poskitt KJ, Dunn HG. Positron emission tomography studies of the dopamine system in Rett syndrome [abstr]. Neurology 1998; 50:A7.
80. Maguire D, Bachman C. Anaesthesia and Rett syndrome: a case report. Can J Anaesth 1989; 36:478-481.
81. Brašić JR, Barnett JY, Nadrich RH, Kaplan D, Ahmad R, Rodriguez M, Mendonça MF. Evaluation of self-injurious tics [abstr]. 3rd International Scientific Symposium on Tourette Syndrome, New York, June 4-6, 1999, p 19.
82. Brašić JR, Zagzag D, Kowalik S, Prichep L, John ER, Buchsbaum M, Barnett JY, Nadrich RH, Kaplan D, Ahmad R, Mendonça MF, Rodriguez M, Bronson B, Cancro R, Kurz L, Brathwaite C. Chronic motor tics are a manifestation of progressive catatonia [abstr]. 3rd International Scientific Symposium on Tourette Syndrome, New York, June 4-6, 1999, p 19.
83. Ringman JM, Jankovic J. Occurrence of tics in Asperger’s syndrome and autistic disorder. J Child Neurol 2000; 15:394-400.
84. Kadesjo B, Gillberg C. Tourette’s disorder: epidemiology and comorbidity in primary school children. J Am Acad Child Adolesc Psychiatry 2000; 39:548-555.
85. Baron-Cohen S, Scahill VL, Izaguirre J, Hornsey H, Robertson MM. The prevalence of Gilles de la Tourette syndrome in children and adolescents with autism: a large scale study. Psychol Med 1999; 29:1151-1159.
86. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006-1011.
87. Goodman W, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989; 46:1012-1016.
88. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989; 28:566-573.
89. Leckman JF, Towbin KE, Ort SI, Cohen DJ. Clinical assessment of tic disorder severity. In: Cohen DJ, Bruun RD, Leckman JF, eds. Tourette’s Syndrome and Tic Disorders. New York: John Wiley & Sons, 1988:55-78.
90. Arnold LE, Aman MG, Martin A, Collier-Crespin A, Vitiello B, Tierney E, Asarnow R, Bell-Bradshaw F, Freeman BJ, Gates-Ulanet P, Klin A, McCracken JT, McDougle CJ, McGough JJ, Posey DJ, Scahill L, Swiezy NB, Ritz L, Volkmar F. Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. J Autism Dev Disord 2000; 30:99-111.
91. Brasic JR, Barnett JY, Ahn SC, Roncoli M, Nadrich RH, Ahmad R. Characterization of movement disorders in prepubertal boys with autistic disorder [abstr]. Mov Disord 1996; 11(suppl 1):59.
92. Würbel H, Freire R, Nicol CJ. Prevention of stereotypic wire-gnawing in laboratory mice: effects on behaviour and implications for stereotypy as a coping response. Behav Proc 1998; 42:61-72.
93. Brown DW. Autism, Asperger’s syndrome and the Crick-Mitchison theory of the biological function of REM sleep. Med Hypotheses 1996; 47:399-403.
94. Ross LL, Yu D, Kropla WC. Stereotyped behavior in developmentally delayed or autistic populations: rhythmic or nonrhythmic? Behav Modif 1998; 22:321-334.
95. Ridley RM. The psychology of perseverative and stereotyped behaviour. Prog Neurobiol 1994; 44:221-231.
96. Lewis MH, Bodfish JW. Repetitive behavior disorders in autism. Ment Retard Dev Disabil Res Rev 1998; 4(2):80-89.
97. Nijhof G, Joha D, Pekelharing H. Aspects of stereotypic behaviour among autistic persons: a study of the literature. Br J Dev Disabil 1998; 44:3-13.
98. Magulac M, Landsverk J, Golshan S, Jeste DV. Abnormal involuntary movements in neuroleptic-naı¨ve children and adolescents. Can J Psychiatry 1999; 44:368-373.
99. Powell SB, Newman HA, Pendergast JF, Lewis MH. A rodent model of spontaneous stereotypy: initial characterization of developmental, environmental, and neurobiological factors. Physiol Behav 1999; 66:355-363.
100. Antoniou K, Kafetzopoulos E, Papadopoulou-Daifoti Z, Hyphantis T, Marselos M. d-amphetamine, cocaine and caffeine: a comparative study of acute effects on locomotor activity and behavioural patterns in rats. Neurosci Biobehav Rev 1998; 23:189-196.
101. Barik S, de Beaurepaire R. Evidence for a functional role of the dopamine D3 receptors in the cerebellum. Brain Res 1996; 737:347-350.
102. Chabrol H, Bonnet D, Roge B. Psychopharmacologie de l’autisme [the psychopharmacology of autism]. Ence´phale 1996; 22:197-203.
103. Buitelaar JK, Dekker MEM, van Ree JM, van Engeland H. A controlled trial with ORG 2766, an ACTH-(4-9) analog, in 50 relatively able children with autism. Eur Neuropharmacol 1996; 6:13-19.
104. Cazzullo AG, Musetti MC, Musetti L, Bajo S, Sacerdote P, Panerai A. β-Endophin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children. Eur Neuropsychopharmacol 1999; 9:361-366.
105. Hollander E, Kaplan A, Cartwright C, Reichman D. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J Child Neurol 2000; 15:132-135.
106. Posey DJ, McDougle CJ. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry 2000; 8:45-63.
107. Brasic JR, Barnett JY, Kaplan D, Sheitman BB, Aisemberg P, Lafargue RT, Kowalik S, Clark A, Tsaltas MO, Young JG. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology 1994; 44:1309-1312.
108. Brašić JR, Barnett JY, Sheitman BB, Lafargue RT, Kowalik S, Kaplan D, Tsaltas MO, Ahmad R, Nadrich RH, Mendonça MF. Behavioral effects of clomipramine on prepubertal boys with autistic disorder and severe mental retardation. CNS Spectrums: Int J Neuropsychiatr Med 1998; 3(10):39-46.
109. Brašić JR, Barnett JY, Sheitman BB, Tsaltas MO. Adverse effects of clomipramine [letter]. J Am Acad Child Adolesc Psychiatry 1997; 36:1165-1166.
110. Sanchez LE, Campbell M, Small AM, Cueva JE, Armenteros JL, Adams PB. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 1996; 35:537-544.
111. McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 2000; 30:427-435.
112. Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebocontrolled, crossover study. J Clin Psychopharmacol 2001; 21:440-444.
113. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53:1001-1008.
114. Harvey RJ. Cooray SE. The effective treatment of severe repetitive behaviour with fluvoxamine in a 20 year old autistic female. Int Clin Psychopharmacol 1995; 10: 201-203.
115. Kutcher SP. Child and Adolescent Psychopharmacology. Philadelphia: WB Saunders, 1997.
116. Simpson RL. Early intervention with children with autism: the search for best practices. J Assoc Pers Sev Handicaps 1999; 24:218-221.
117. Smith T, Antolovich M. Parental perceptions of supplemental interventions received by young children with autism in intensive behavior analytic treatment. Behav Interv 2000; 15:83-97.
118. Saunders MD, Saunders RR, Marquis JG. Comparison of reinforcement schedules in the reduction of stereotypy with supported routines. Res Dev Disabil 1998; 19: 99-122.
119. Morrison K, Rosales-Ruiz J. The effect of object preferences on task performance and stereotypy in a child with autism. Res Dev Disabil 1997; 18:127-137.
120. Celiberti DA, Bobo HE, Kelly KS, Harris SL, Handelman JS. The differential and temporal effects of antecedent exercise on the self-stimulatory behavior of a child with autism. Res Dev Disabil 1997; 18:139-150.
121. Symons F, Davis M. Instructional conditions and stereotyped behavior: the function of prompts. J Behav Ther Exp Psychiatry 1994 25:317-324.
122. Duker PC, Schaapveld M. Increasing on-task behaviour through interruption prompting. J Intellect Disabil Res 1996; 40:291-297.
123. Sweeney HM, LeBlanc JM. Effects of task size on work-related and aberrant behaviors of youths with autism and mental retardation. Res Dev Disabil 1995; 16: 97-115.
124. Trepagnier CG. Virtual environments for the investigation and rehabilitation of cognitive and perceptual impairments. Neurorehabilitation 1999; 12:63-72.
125. Willenberg H. Probleme der Klassifikation heimlicher Selbstscha¨digung und Entwicklung eines Alternativvorschlages [problems of classifying secret self-injurious behaviors and development of an alternative proposal]. Psychother Psychosom Med Psychol 1994; 44:331-336.
126. Szymanski L, Kedesdy J, Sulkes S, Cutler A, Stevens-Our P. Naltrexone in treatment of self injurious behavior: a clinical study. Res Dev Disabil 1987; 8:179-190.
127. Wieseler NA, Hanson RH, Chamberlain TP, Thompson T. Functional taxonomy of stereotypic and self-injurious behavior. Ment Retard 1985; 23:230-234.
128. Schroeder SR, Schroeder CS, Smith B, Dalldorf J. Prevalence of self-injurious behaviors in a large state facility for the retarded: a three-year follow-up study. J Autism Child Schizophr 1978; 8:261-269.
129. Rapin I. Appropriate investigations for clinical care versus research in children with autism. Brain Dev 1999; 21:152-156.
130. Matson JL, Hamilton M, Duncan D, Bamburg J, Smiroldo B, Anderson S, Baglio C, Williams D, Kirkpatrick-Sanchez S. Characteristics of stereotypic movement disorder and self-injurious behavior assessed with the Diagnostic Assessment for the Severely Handicapped (DASH-II). Res Dev Disabil 1997; 18:457-469.
131. King BH, Lynn D. Self-injurious behavior in mental retardation. Curr Opin Psychiatry 1998; 11:523-526.
132. Office of Medical Applications of Research, National Institutes of Health. Treatment of destructive behaviors in persons with developmental disabilities. Conn Med 1990; 54:65-74.
133. Russo DC, Carr EG, Lovaas OI. Self-injury in pediatric populations. In: Ferguson JM, Taylor CB, eds. The Comprehensive Handbook of Behavioral Medicine. Vol 3. New York: Spectrum Publications, 1980:23-41.
134. Eisenhauer GL, Woody RC. Self-mutilation and Tourette’s disorder. J Child Neurol 1987; 2:265-267.
135. Jankovic J. Orofacial and other self-mutilations. In: Jankovic J, Tolosa E, eds. Facial Dyskinesias. Advances in Neurology, Vol 49. New York: Raven Press, 1988:365-381.
136. Stodgell CJ, Loupe PS, Schroeder SR, Tessel RE. Cross-sensitization between footshock stress and apomorphine on self-injurious behavior and neostriatal catecholamines in a rat model of Lesch-Nyhan syndrome. Brain Res 1998; 783:10-18.
137. Gualtieri CT. The measurement of self-injurious behavior. J Neuropsychiatry Clin Neurosci 1991; 3:S30-S34.
138. Gedye A. Extreme self-injury attributed to frontal lobe seizures. Am JMent Retard 1989; 94:20-26.
139. Dura JR, Mulick JA, Rasnake LK. Prevalence of stereotypy among institutionalized nonambulatory profoundly mentally retarded people. Am J Ment Defic 1987; 91:548-549.
140. Fovel JT, Lash PS, Barron DA, Jr., Roberts MS. A survey of self-restraint, selfinjury, and other maladaptive behaviors in an institutionalized retarded population. Res Dev Disabil 1989; 10:377-382.
141. Griffin JC, Ricketts RW, Williams DE, Locke BJ, Altmeyer BK, Stark MT. A community survey of self-injurious behavior among developmentally disabled children and adolescents. Hosp Commun Psychiatry 1987; 38:959-963.
142. Hill RK, Bruininks RH. Maladaptive behavior of mentally retarded individuals in residential facilities. Am J Ment Defic 1984; 88:380-387.
143. Oliver C, Murphy GH, Corbett JA. Self-injurious behaviour in people with mental handicap: a total population study. J Ment Defic Res 1987; 31:147-162.
144. Putnam N, Stein M. Self-inflicted injuries in childhood: a review and diagnostic approach. Clin Pediatr 1985; 24:514-518.
145. Rojahn J. Self-injurious and stereotypic behavior of noninstitutionalized mentally retarded people: prevalence and classification. Am J Ment Defic 1986; 91:268-276.
146. Matson JL, Bamburg JW. A descriptive study of pica behavior in persons with mental retardation. J Dev Phys Disabil 1999; 11:353-361.
147. Holburn CS. Aerophagia: an uncommon form of self-injury. Am J Ment Defic 1986; 91:201-203.
148. Levison CA. The development of head banging in a young rhesus monkey. Am J Ment Defic 1970; 75:323-328.
149. Allyn G, Deyme A, Bègue I. Self-fighting syndrome in macaques. I. A representative case study. Primates 1976; 17: 1-22.
150. Jones IH, Barraclough BM. Auto-mutilation in animals and its relevance to selfinjury in man. Acta Psychiatr Scand 1978; 58:40-47.
151. Cataldo MF, Harris J. The biological basis for self-injury in the mentally retarded. Anal Interv Dev Disabil 1982; 2:21-38.
152. Kelley WM, Wyngaarden JB. Clinical syndromes associated with HGPRT deficiency. In: Stanbury JB, Wyngaarden JB, et al., eds. The Metabolic Basis of Inherited Disease. 5th ed. New York: McGraw-Hill, 1983:1115-1143.
153. Lesch M, Nyhan WL. A familial disorder of uric acid metabolism and central nervous system function. Am J Med 1964; 36:561-570.
154. Shear CS, Nyhan WL, Kirman BH, Stern J. Self-mutilative behavior as a feature of the de Lange syndrome. J Pediatr 1971; 78:506-509.
155. Gualtieri CT. The differential diagnosis of self-injurious behavior in mentally retarded people. Psychopharmacol Bull 1989; 25(3):358-363.
156. Jones IH. Self-injury: toward a biological basis. Perspect Biol Med 1982; 26:137-150.
157. Ciaranello RD, Anders TF, Barchas JD, Berger PA, Cann HM. The use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome. Child Psychiatry Hum Dev 1976; 7:127-133.
158. Lloyd KG, Hornykiewicz O, Davidson L, Shannak K, Farley I, Goldstein M, Shibuya M, Kelley WN, Fox IH. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med 1981; 305:1106-1111.
159. Lake CR, Ziegler MG. Lesch-Nyhan syndrome: low dopamine-beta-hydroxylase activity and diminished sympathetic response to stress and posture. Science 1977; 196:905-906.
160. Mizuno TI, Yugari Y. Self mutilation in Lesch-Nyhan syndrome [letter]. Lancet 1974; 1(7860):761.
161. Nyhan WL, Johnson HG, Kaufman IA, Jones KL. Serotonergic approaches to the modification of behavior in the Lesch-Nyhan syndrome. Appl Res Ment Retard 1980; 1:25-40.
162. Mailis A. Compulsive targeted self-injurious behaviour in humans with neuropathic pain: a counterpart of animal autotomy? Four case reports and literature review. Pain 1996; 64:569-578.
163. Ritvo ER, Ornitz EM, La Franchi S. Frequency of repetitive behaviors in early infantile autism and its variants. Arch Gen Psychiatry 1968; 19:341-347.
164. Delcomyn F. Neural basis of rhythmic behavior in animals. Science 1980; 210: 492-498.
165. Olson GA, Olson RD, Vaccarino AL, Kastin AJ. Endogenous opiates: 1997. Peptides 1998; 19:1791-1843.
166. Beckwith BE, Couk DI, Schumacher K. Failure of naloxone to reduce self-injurious behavior in two developmentally disabled females. Appl Res Ment Retard 1986; 7:183-188.
167. Davidson PW, Kleene BM, Carroll M, Rockowitz RJ. Effects of naloxone on selfinjurious behavior: a case study. Appl Res Ment Retard 1983; 4:1-4.
168. Sandman CA, Barron JL, Crinella FM, Donnelly JF. Influence of naloxone on brain and behavior of a self-injurious woman. Biol Psychiatry 1987; 22:899-906.
169. Sandman CA, Datta PC, Barron J, Hoehler FK, Williams C, Swanson JM. Naloxone attenuates self-abusive behavior in developmentally disabled clients. Appl Res Ment Retard 1983; 4:5-11.
170. Ballinger BR, Armstrong J, Presley AS, Reid AH. Use of a standardized psychiatric interview in mentally handicapped patients. Br J Psychiatry 1975; 127:540-544.
171. Goldberg DP, Cooper B, Eastwood MR, Kedward HB, Shepherd M. A standardized psychiatric interview for use in community surveys. Br J Prev Soc Med 1970; 24:18-23.
172. Read SG, Batchelor DH. Violent and self-injurious behaviour in mentally handicapped patients—psychopharmacological control. Int Clin Psychopharmacol 1986; 1(suppl 1):63-74.
173. Campbell M, Adams P, Small AM, Tesch LM, Curren EL. Naltrexone in infantile autism. Psychopharmacol Bull 1988; 24(1):135-139.
174. Sandyk R. Naloxone abolishes self-injuring in a mentally retarded child. Ann Neurol 1985; 17:520.
175. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R-Patient Edition (SCID-P, Version 1.0). Washington, DC: American Psychiatric Publishing, 1990.
176. Bernstein GA, Hughes JR, Mitchell JE, Thompson T. Effects of narcotic antagonists on self-injurious behavior: a single case study. J Am Acad Child Adolesc Psychiatry 1987; 26:886-889.
177. Iwata BA, Pace GM, Kissel RC, Nau PA, Farber JM. The Self-Injury Trauma (SIT) Scale: a method for quantifying surface tissue damage caused by self-injurious behavior. J Appl Behav Anal 1990; 23:99-110.
178. Baker SP, O’Neill B, Haddon W, Jr., Long WB. The Injury Severity Score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma 1974; 14(3):187-196.
179. Barancik JI, Chatterjee BF. Methodological considerations in the use of the Abbreviated Injury Scale in trauma epidemiology. J Trauma 1981; 21(8):627-631.
180. Champion HR, Sacco WJ, Lepper RL, Atzinger EM, Copes WS, Prall RH. An anatomic index of injury severity. J Trauma 1980; 20(3):197-202.
181. Committee on Medical Aspects of Automotive Safety. Rating the severity of tissue damage. I. The abbreviated scale. JAMA 1971; 215:277-280.
182. Committee on Medical Aspects of Automotive Safety. Rating the severity of tissue damage. II. The comprehensive scale. JAMA 1972; 220:717-720.
183. Greenspan L, McLellan BA, Greig H. Abbreviated Injury Scale and Injury Severity Score: a scoring chart. J Trauma 1985; 25:60-64.
184. Mayer T, Matlak ME, Johnson DG, Walker ML. The modified injury severity scale in pediatric multiple trauma patients. J Pediatr Surg 1980; 15:719-726.
185. Brasic JR, Kisnad HV, Barnett JY, Kowalik S, Ahn SC, Nadrich RH, Mendonca MF. Clinical assessment of self-injurious behaviors in people with movement disorders [abstr]. Mov Disord 2001; 16(suppl 1):S46.
186. Gorman-Smith D, Matson JL. A review of treatment research for self-injurious and stereotyped responding. J Ment Defic Res 1985; 29:295-308.
187. Lundervold D, Bourland G. Quantitative analysis of treatment of aggression, selfinjury, and property destruction. Behav Modif 1988; 12:590-617.
188. Durand VM, Carr EG. Operant learning methods with chronic schizophrenia and autism: aberrant behavior. In: Matson JL, ed. Chronic Schizophrenia and Adult Autism. New York: Springer, 1989:231-273.
189. Durand VM, Crimmins DB, Caulfield M, Taylor J. Reinforcer assessment. I. Using problem behavior to select reinforcers. J Assoc Pers Sev Handicaps 1989; 14:113-126.
190. Favell JE, Azrin NH, Baumeister AA, Carr EG, Dorsey MF, Forehand R, Foxx RM, Lovaas OI, Rincover A, Risley TR, Romanczyk RG, Russo CD, Schroeder SR, Solnick JV. The treatment of self-injurious behavior. Behav Ther 1983:13: 529-554.
191. Iwata BA, Dorsey MF, Slifer KJ, et al. Toward a functional analysis of self injury. Anal Interv Dev Disabil 1982; 2:3-20.
192. Repp AC, Felce D, Barton LE. Basing the treatment of stereotypic and self-injurious behaviors on hypotheses of their causes. J Appl Behav Anal 1988; 21:281-289.
193. Rincover A. Behavioral research in self-injury and self-stimulation. Psychiatr Clin North Am 1986; 9:755-766.
194. Silverstein BJ, Olvera DR., Schalock R. Allocating direct-care resources for treatment of maladaptive behavior: the Staff Intensity Scale. Ment Retard 1987; 25: 91-100.
195. Gerdtz J. Evaluating behavioral treatment of disruptive classroom behaviors of an adolescent with autism. Res Soc Work Pract 2000; 10:98-110.
196. Dawson JE, Matson JL, Cherry KE. An analysis of maladaptive behaviors in persons with autism, PPD-NOS, and mental retardation. Res Dev Disabil 1998; 19: 439-448.
197. Martin NT, Gaffan EA, Williams T. Experimental functional analyses for challenging behavior: a study of validity and reliability. Res Dev Disabil 1999; 20: 125-146.
198. Lockwood K, Williams DE. Treatment and extended follow-up of chronic hand mouthing. J Behav Ther Exp Psychiatry 1994; 25(2):161-169.
199. Miller BY, Jones RSP. Reducing stereotyped behaviour: a comparison of two methods of programming differential reinforcement. Br J Clin Psychol 1997; 36(2):297-302.
200. Corbett J. Aversion for the treatment of self-injurious behaviour. J Ment Defic Res 1975; 19:79-95.
201. Barrett RP, Matson JL, Shapiro ES, Ollendick TH. A comparison of punishment and DRO procedures for treating stereotypic behavior of mentally retarded children. Appl Res Ment Retard 1981; 2:247-256.
202. Duker PC, Seys DM. A quasi-experimental study on the effect of electrical aversion treatment on imposed mechanical restraint for severe self-injurious behavior. Res Dev Disabil 2000; 21:235-242.
203. Singh NN, Watson JE, Winton ASW. Treating self-injury: water spray versus facial screening or forced arm exercise. J Appl Behav Anal 1986; 19:403-410.
204. Peri T, Ben-Shakhar G, Orr, SP, Shalev AY. Psychophysiologic assessment of aversive conditioning in posttraumatic stress disorder. Biol Psychiatry 2000; 47: 512-519.
205. Altmeyer BK, Williams DE, Sams V. Treatment of severe self-injurious and aggressive biting. J Behav Ther Exp Psychiatry 1985; 16:169-172.
206. Brašić JR, Fogelman D. Clinician safety. Psychiatr Clin North Am 1999; 22:923-940.
207. Azrin NH, Kaplan SJ, Foxx RM. Autism reversal: eliminating stereotyped selfstimulation of retarded individuals. Am J Ment Defic 1973; 78:241-248.
208. Silverman K, Watanabe K, Marshall AM, Baer DM. Reducing self-injury and corresponding self-restraint through the strategic use of protective clothing. J Appl Behav Anal 1984; 17:545-552.
209. Pace GM, Iwata BA, Edwards GL, McCosh KC. Stimulus fading and transfer in the treatment of self-restraint and self-injurious behavior. J Appl Behav Anal1986; 19:381-389.
210. Luiselli JK. Modification of self-injurious behavior: an analysis of the use of contingently applied protective equipment. Behav Modif 1986; 10:191-204.
211. Luiselli JK. Contingent glove wearing for the treatment of self-excoriating behavior in a sensory-impaired adolescent. Behav Modif 1989; 13:65-73.
212. Lovaas I, Newson C, Hickman C. Self-stimulatory behavior and perceptual reinforcement. J Appl Behav Anal 1987; 20:45-68.
213. Clauser B, Gould K. Visual screening as a reductive procedure: an examination of generalization and duration. Behav Residential Treat 1988; 3:51-61.
214. Watson J, Singh NN, Winton ASW. Suppressive effects of visual and facial screening on self-injurious finger-sucking. Am J Ment Defic 1986; 90:526-534.
215. Winton ASW, Singh NN, Dawson MJ. Effects of facial screening and blindfold on self-injurious behavior. Appl Res Ment Retard 1984; 5:29-42.
216. Goodall E, Corbett J. Relationships between sensory stimulation and stereotyped behaviour in severely mentally retarded and autistic children. J Ment Defic Res 1982; 26:163-175.
217. Stroh G, Buick D. The effect of relative sensory isolation on the behaviour of two autistic children. In: Hutt SJ, Hutt C, eds. Behaviour Studies in Psychiatry. Oxford, England: Pergamon Press, 1970:161-174.
218. Luiselli JK. Use of sensory extinction in treating self-injurious behavior: a cautionary note. The Behavior Therapist 1984; 7:142-160.
219. Norton RS. Side effects of sensory extinction and an alternative procedure for high rates of self-injury. The Behavior Therapist 1985:8:86-87.
220. Rincover A. Sensory extinction: some answers and questions. The Behavior Therapist 1985; 8:177-178.
221. Azrin NH, Besalel VA, Jamner JP, Caputo JN. Comparative study of behavioral methods of treating severe self-injury. Behav Residential Treat 1988; 3:119-152.
222. Haring TG, Breen CG, Pitts-Conway V, Gaylord-Ross R. Use of differential reinforcemnt of other behavior during dyadic instruction to reduce stereotyped behavior of autistic students. Am J Ment Defic 1986; 90:694-702.
223. Matson JL, Keyes JB. A comparison of DRO to movement suppression time-out and DRO with two self-injurious and aggressive mentally retarded adults. Res Dev Disabil 1990; 11:111-120.
224. Parrish JM, Iwata BA, Dorsey MF, Bunck TJ, Slifer KJ. Behavior analysis, program development, and transfer of control in the treatment of self-injury. J Behav Ther Exp Psychiatry 1985; 16:159-167.
225. Repp AC, Deitz SM, Speir NC. Reducing stereotypic responding of retarded persons by differential reinforcement of other behavior. Am J Ment Defic 1974; 79: 279-284.
226. Tarpley HD, Schroeder SR. Comparison of DRO and DRI on rate of suppression of self-injurious behavior. Am J Ment Defic 1979; 84:188-194.
227. Hegel MT, Ferguson RJ. Differential reinforcement of other behavior (DRO) to reduce aggressive behavior following traumatic brain injury. Behav Modif 2000; 24(1):94-101.
228. Luiselli JK. Functional assessment and treatment of aggressive and destructive behaviors in a child victim of physical abuse. J Behav Ther Exp Psychiatry 1996; 27:41-49.
229. Paisey TJH, Whitney RB, Moore J. Person-treatment interactions across nonaversive response-deceleration procedures for self-injury: a case study of effects and side effects. Behav Residential Treat 1989; 4:69-88.
230. Lancioni GE, O’Reilly MF. A review of research on physical exercise with people with severe and profound developmental disabilities. Res Dev Disabil 1998; 19: 477-492.
231. Repp AC, Singh NN, Olinger E, Olson DR. The use of functional analyses to test causes of self-injurious behaviour: rationale, current status and future directions. J Ment Defic Res 1990; 34:95-105.
232. Durand VM, Crimmins DB. Identifying the variables maintaining self-injurious behavior. J Autism Dev Disord 1988; 18:99-117.
233. Iwata BA, Pace GM, Kalsher MJ, Cowdery GE, Cataldo MF. Experimental analysis and extinction of self-injurious escape behavior. J Appl Behav Anal 1990; 23: 11-27.
234. Steege MW, Wacker DP, Cigrand KC, Berg WK, Novak CG, Reimers TM, Sasso GM, DeRaad A. Use of negative reinforcement in the treatment of self-injurious behavior. J Appl Behav Anal 1990; 23:459-467.
235. Bourland G, Jablonski EM, Lockhart DL. Multiple-behavior comparison of group and individual instruction of persons with mental retardation. Ment Retard 1988; 26:39-46.
236. Durand VM. Self-injurious behavior as intentional communication. Adv Learn Behav Disabil 1986; 5:141-155.
237. Bird F, Dores PA, Moniz D, Robinson J. Reducing severe aggressive and selfinjurious behaviors with functional communication training. Am J Ment Retard 1989; 94:37-48.
238. Carr EG, Durand VM. See me, help me. Psychol Today 1987; 21(11):62-64.
239. Day RM, Johnson WL, Schussler NG. Determining the communicative properties of self-injury: research, assessment, and treatment implications. Adv Learn Behav Disabil 1986; 5:117-139.
240. Day RM, Rea JA, Schussler NG, Larsen SE, Johnson WL. A functionally based approach to the treatment of self-injurious behavior. Behav Modif 1988; 12:565-589.
241. Durand VM, Carr EG. Functional communication training to reduce challenging behavior: maintenance and application in new settings. J Appl Behav Anal 1991; 24:251-264.
242. Durand VM, Carr EG. Self-injurious behavior: motivating conditions and guidelines for treatment. School Psychol Rev 1985; 14(2):171-176.
243. Braithwaite KL, Richdale AL. Functional communication training to replace challenging behaviors across two behavioral outcomes. Behav Interv 2000; 15:21-36.
244. Schroeder SR, Rojahn J, Mulick JA. Ecobehavioral organization of developmental day care for the chronically self-injurious. J Pediatr Psychol 1978; 3(2):81-88.
245. Arnaud M.É tude des ste´re´otypies dans l’autisme infantile [a study of stereotypies in infantile autism]. Psychiatr Enfant 1986; 29:387-420.
246. Kennedy H, Moran GS. The developmental roots of self-injury and response to pain in a 4-year-old boy. Psychoanal Study Child 1984; 39:195-212.
247. Kerbeshian J, Burd L, Avery K. Pharmacotherapy of autism: a review and clinical approach. J Dev Phys Disabil 2001; 13:199-228.
248. Madrid AL, State MW, King BH. Pharmacologic management of psychiatric and behavioral symptoms in mental retardation. Child Adolesc Psychiatr Clin North Am 2000; 9:225-243.
249. Goldstein M, Kuga S. Dopamine (DA) agonist induced compulsive biting (CB) behavior in monkeys: animal model for Lesch-Nyhan syndrome [abstr]. Soc Neurosci Abstracts 1984; 10(part 2):804.
250. Gualtieri CT, Schroeder SR. Pharmacotherapy for self-injurious behavior: preliminary tests of the D1 hypothesis. Psychopharmacol Bull 1989; 25(3):364-371.
251. Allen SM, Freeman JN, Davis WM. Evaluation of risperidone in the neonatal 6-hydroxydopamine model of Lesch-Nyhan syndrome. Pharmacol Biochem Behav 1998; 59:327-330.
252. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord 1997; 27:313-323.
253. Cohen SA, Ihrig K, Lott RS, Kerrick JM. Risperidone for aggression and selfinjurious behavior in adults with mental retardation. J Autism Dev Disord 1998; 28:229-233.
254. Mendonca MF, Brasic JR, Perry R, Krigsman S, Lucien M, Petty CB. Risperidone ameliorates large amplitude complex stereotypies and high activity level in a boy with autistic disorder [abstr]. Mov Disord 2001; 16(suppl 1):S36.
255. DeVane CL, Nemeroff CB. An evaluation of risperidone drug interactions. J Clin Psychopharmacol 2001; 21:408-416.
256. Drug interactions of risperidone. Child Adolesc Psychopharmacol News 2002; 7(2):12.
257. Aman MG, Arnold LE, Armstrong SC. Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Ment Retard Dev Disabil Res Rev 1999; 5:279-289.
258. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an openlabel pilot study. J Clin Psychopharmacol 1999; 19:37-44.
259. Aman MG, Madrid A. Atypical antipsychotics in persons with developmental disabilities. Ment Retard Dev Disabil Res Rev 1999; 5:253-263.
260. Divalproex sodium in autism spectrum disorders. Child Adolesc Psychopharmacol News 2002; 7(2):10-11.
261. Hollander E, Dolgoff-Kaspar R, et al. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001; 62:530-534.
262. Ereshefsky L, Riesenman C, Lam YWF. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry 1996; 57(suppl 8):17-25.
263. Oesterheld JR, Shader RI. Cytochromes: a primer for child and adolescent psychiatrists. J Am Acad Child Adolesc Psychiatry 1998; 37:447-450.
264. Luchins DJ, Dojka D. Lithium and propranolol in aggression and self-injurious behavior in the mentally retarded. Psychopharmacol Bull 1989; 25(3):372-375.
265. Reents SB, Beck CA Jr. Naloxone and naltrexone: application in COPD. Chest 1988; 93:217-219.
266. Cohen MR, Cohen RM, Pickar D, Murphy DL, Bunney WE Jr. Physiological effects of high dose naloxone administration to normal adults. Life Sci 1982; 30: 2025-2031.
267. Grevert P, Albert LH, Inturrisi CE, Goldstein A. Effects of eight-hour naloxone infusions on human subjects. Biol Psychiatry 1983; 18:1375-1392.
268. Newhouse PA, Tariot PN, Gross M, Murphy DL, Cohen RM. Failure of high dose naloxone to relieve tardive dyskinesia [letter]. J Clin Psychopharmacol 1987; 7: 364-365.
269. Nasrallah HA, Varney N, Coffman JA, Bayless J, Chapman S. Effects of naloxone on cognitive deficits following electroconvulsive therapy. Psychopharmacol Bull 1985; 21(1):89-90.
270. Pollock J, Kornetsky C. Naloxone prevents and blocks the emergence of neurolepticmediated oral stereotypic behaviors. Neuropsychopharmacology 1991; 4:245-249.
271. Richardson JS, Zaleski WA. Naloxone and self-mutilation. Biol Psychiatry 1983; 18:99-101.
272. Barrett RP, Feinstein C, Hole WT. Effects of naloxone and naltrexone on selfinjury: a double-blind, placebo-controlled analysis. Am J Ment Retard 1989; 93: 644-651.
273. Malcolm R, Gabel T, Morton A. More on idiosyncratic reaction to naltrexone [letter]. Am J Psychiatry 1989; 146:124-125.
274. Rascol O, Fabre N, Blin O, Poulik J, Sabatini U, Senard J-M, Ane´ M, Montastruc J-L, Rascol A. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson’s disease. Mov Disord 1994; 9:437-440.
275. Sandyk R, Iacono RP. Naltrexone attenuates the antiparkinsonian effects of picoTesla range magnetic fields. Int J Neurosci 1994; 78:111-122.
276. Dennis K. Naltrexone. Treatment Issues: The GMHC Newsletter of Experimental AIDS Therapies 1990; 4(1):1-2.
277. Wildt L, Leyendecker G. Induction of ovulation by the chronic administration of naltrexone in hypothalamic amenorrhea. J Clin EndocrinolMetab 1987; 64:1334-1335.
278. Igoin-Apfelbaum L, Apfelbaum M. Naltrexone and bulimic symptoms [letter]. Lancet 1987; 2(8567):1087-1088.
279. Tennant FS Jr, Wild J. Naltrexone treatment for postconcussional syndrome. Am J Psychiatry 1987; 144:813-814.
280. Herman BH, Hammock MK, Arthur-Smith A, Egan J, Chatoor I, Werner A, Zelnik N. Naltrexone decreases self-injurious behavior. Ann Neurol 1987; 22:550-552.
281. Herman BH, Hammock MK, Egan J, Feinstein C, Chatoor I, Boeckx R, Zelnick N, Jack R, Rosenquist J. Naltrexone induces dose-dependent decreases in selfinjurious behavior [abstr]. Abstr Soc Neurosci 1985; 11:468.
282. Garcia D, Smith RG. Using analog baselines to assess the effects of naltrexone on self-injurious behavior. Res Dev Disabil 1999; 20:1-21.
283. Sandman CA, Hetrick W, Taylor DV, Marion SD, Touchette P, Barron JL, Martinezzi V, Steinberg RM. Long-term effects of naltrexone on self-injurious behavior. Am J Ment Retard 2000; 105:103-117.
284. Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 1993; 32:1283-1291.
285. Campbell M, Anderson LT, Small AM, Locascio JJ, Lynch NS, Choroco MC. Naltrexone in autistic children: a double-blind and placebo-controlled study. Psychopharmacol Bull 1990; 26(1):130-135.
286. Campbell M, Overall JE, Small AM, Sokol MS, Spencer EK, Adams P, Foltz RL, Monti KM, Perry R, Nobler M, Roberts E. Naltrexone in autistic children: an acute open dose range tolerance trial. J Am Acad Child Adolesc Psychiatry 1989; 28: 200-206.
287. Campbell M. Resolved: autistic children should have a trial of naltrexone—affirmative: Magda Campbell, MD. J Am Acad Child Adolesc Psychiatry 1996; 35: 246-247.
288. Herman BH, Chatoor I. Naltrexone shown to decrease frequency of self-injurious behavior. The Psychiatric Times 1991; 8(8):32-39.
289. Leboyer M, Bouvard MP, Dugas M. Effects of naltrexone on infantile autism [letter]. Lancet 1988; 1(8587):715.
290. Lienemann J, Walker F. Naltrexone for treatment of self-injury [letter]. Am J Psychiatry 1989; 146:1639-1640.
291. Sandman CA, Hetrick WP, Taylor DV, Barron JL, Touchette P, Lott I, Crinella F, Martinazzi V. Naltrexone reduces self-injury and improves learning. Exp Clin Psychopharmacol 1993; 1:242-258.
292. Walters AS, Barrett RP, Feinstein C, Mercurio A, Hole WT. A case report of naltrexone treatment of self-injury and social withdrawal in autism. J Autism Dev Disord 1990; 20:169-176.
293. Chisholm T, Morehouse RL. Adult headbanging: sleep studies and treatment. Sleep 1996; 19:343-346.
294. Durand VM. A behavioral/pharmacological intervention for the treatment of severe self-injurious behavior. J Autism Dev Disord 1982; 12:243-251.
295. Farber JM. Psychopharmacology of self-injurious behavior in the mentally retarded. J Am Acad Child Adolesc Psychiatry 1987; 26:296-302.
296. Luiselli JK. Behavior analysis of pharmacological and contingency management interventions for self-injury. J Behav Ther Exp Psychiatry 1986; 17:275-284.
297. Luiselli JK, Evans TP, Boyce DA. Pharmacological assessment and comprehend sive behavioral intervention in a case of pediatric self-injury. J Clin Child Psychol 1986; 15:323-326.
298. Singh NN, Winton ASW. Behavioral monitoring of pharmacological interventions for self-injury. Appl Res Ment Retard 1984; 5:161-170.
299. Lapierre YD, Reesal R. Pharmacologic management of aggressivity and self-mutilation in the mentally retarded. Psychiatr Clin North Am 1986; 9:745-754.
300. Singh NN, Millichamp CJ. Effects of medication on the self-injurious behavior of mentally retarded persons. Psychiatr Aspects Ment Retard Rev 1984; 3(4):13-16.
301. Singh NN, Millichamp CJ. Pharmacological treatment of self-injurious behavior in mentally retarded persons. J Autism Dev Disord 1985; 15:257-267.
302. Swett C, Jr. Psychotropic medications used during mechanical restraint of patients. Curr Ther Res 1985:38(4):621-626.
303. Brašić JR, Barnett JY, Zelhof R, Tarpley H. Dopamine antagonists ameliorate the dyskinesias, aggression, and inattention of persons with mental retardation referred to psychiatric clinics. Ger J Psychiatry 2001; 4(1):9-16. www.gjpsy.unigoettingen/gjp-article-brasic3.pdf.
304. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 1999; 38(suppl):32S-54S.
305. Tsai LY. Psychopharmacology in autism. Psychosom Med 1999; 61:651-665.
306. Duchan JF. Describing the unusual behavior of children with autism. J Commun Disord 1998; 31:93-112.
307. Brašić JR, Young JG. Research design, measures, and statistics. In: Robson KS, ed. Manual of Clinical Child and Adolescent Psychiatry. Revised ed. Washington, DC: American Psychiatric Press, 1994:435-463.
308. Walkup JT, Labellarte MJ, Riddle MA. Commentary: unmasked and uncontrolled medication trials in child and adolescent psychiatry. J Am Acad Child Adolesc Psychiatry 1998; 37:360-363.
309. Martin A, Patzer DK, Volkmar FR. Psychopharmacological treatment of higherfunctioning pervasive developmental disorders. In: Klin A, Volkmar FR, Sparrow SS, eds. Asperger Syndrome. New York: The Guilford Press, 2000:210-228.
310. Matson JL, Bamburg JW, Mayville EA, Pinkston J, Bielecki J, Kuhn D, Smalls Y, Logan JR. Psychopharmacology and mental retardation: a 10 year review (1990-1999). Res Dev Disabil 2000; 21:263-296.
311. Brašić JR, Kaplan D, Young JG: The design and analysis of single-patient randomized clinical trials for children and adolescents with developmental disorders [abstr]. Abstracts of the 12th International Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions, Kyoto, Japan, July 16-20, 1990, Symposium S-84-2:192.
312. Brašić JR, Kaplan D, Young JG: The design and analysis of experiments with N = 1 [abstr]. Abstracts of the Second International Conference on Industrial and Applied Mathematics, Washington, DC, July 8-12, 1991:27.
313. Baving L, Schmidt MH. Evaluated treatment approaches in child and adolescent psychiatry. I. Z Kinder Jugendpsychiatr Psychother 2001; 29:189-205.